In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

High-intensity interval training alters expression of anti-inflammatory cytokine in patients with chronic heart failure: a randomized controlled trial

Session Poster Session 1

Speaker Anderson Ulbrich

Event : ESC Congress 2018

  • Topic : preventive cardiology
  • Sub-topic : Prevention: Exercise
  • Session type : Poster Session

Authors : AZ Ulbrich (Curitiba,BR), VG Angarten (Lisbon,PT), SW Sties (Florianopolis,BR), LS Mara (Florianopolis,BR), A Bittencourt (Porto Alegre,BR), TG Heck (Ijuí,BR), RL Bertin (Curitiba,BR), PIH Bittencourt Jr (Porto Alegre,BR), EL Silva (Florianopolis,BR), T Carvalho (Florianopolis,BR)

Authors:
A.Z. Ulbrich1 , V.G. Angarten2 , S.W. Sties3 , L.S. Mara3 , A. Bittencourt4 , T.G. Heck5 , R.L. Bertin1 , P.I.H. Bittencourt Jr4 , E.L. Silva6 , T. Carvalho3 , 1Federal University of Parana, Medicine - Curitiba - Brazil , 2University of Lisbon, Faculty of Human Motricity - Lisbon - Portugal , 3State University of Santa Catarina - Florianopolis - Brazil , 4Federal University of Rio Grande do Sul - Porto Alegre - Brazil , 5Regional University of the Northwestern - UNIJUI, Physiology Research Group, Department of Life Sciences, - Ijuí - Brazil , 6Federal University of Santa Catarina - Florianopolis - Brazil ,

On behalf: Center of Cardiology and Exercise Medicine

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 87-88

Background: Exercise training is a well-known coadjuvant in heart failure treatment and improves work capacity through skeletal muscle aerobic metabolism. However, effects on inflammatory biomarkers are yet not well established. The present research suggests that moderate exercise training may decrease pro-inflammatory mediators, but it is uncertain whether it could affect their response to high-intensity interval training.

Objective: To determine the effects of different intensities on treadmill training on inflammatory biomarkers in CHF patients.

Methods: 27 CHF patients with ≤40% ejection fraction, males (45–72 years), NYHA functional class II and III. Functional status of patients with CHF were evaluated by using a cardiorespiratory exercise test to measure peak oxygen consumption (VO2max). CHF patients were randomized into two groups to carry out a program of exercise at different intensities. Moderate continuos intensity training (MCIT), exercising with a heart rate corresponding to the aerobic threshold versus high-intensity interval training (HIIT), exercising with a heart rate corresponding to the anaerobic threshold. All groups underwent three months of treadmill exercise (40 min, 3 times / week), for 12 weeks. Plasma samples from venous blood for inflammatory biomarkers (circulating IL-6, IL-1β, IL-10 and TNF-α) were collected at the beginning and at the end of 12 weeks (chronic effect), before and after training session (acute effect). Results are expressed as means ± S.D. analyzed by two-way ANOVA to repeat measures and interaction, followed by Tuckey post-test.

Results: Twenty-two participants (82%) completed the intervention without any severe adverse events. It was observed an improvement in VO2max by 11.2% in the HIIT group and 8.3% in the MCIT group, with between-group differences (p<0.01). The changes in IL-10 (A), IL-1β (B), IL-6 (C) and TNF-α (D) were significant both during and after training (Fig.1).

Conclusion: The exercise training has important clinical effects on anti-inflammatory biomarkers, and the response varied with the intensity of exercise, particularly with HIIT. Trial registration: RBR-6hk9p6; registered on 15 May 2013.

Figure 1. Acute and chronic effects of MCIT and HIIT in CHF patients.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are